Vera Therapeutics financials
$32.50−0.12%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$112.5M | -$125.1M | -$94.2M | -$83.9M | -$80.1M | -$57.2M | -$48.9M | -$49.8M | -$37.3M | -$31.1M | -$27.0M | -$21.8M |
| Net income | -$109.7M | -$122.0M | -$91.1M | -$80.3M | -$76.7M | -$51.4M | -$43.4M | -$46.6M | -$33.7M | -$28.4M | -$25.7M | -$20.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.52 | $-1.69 | $-1.39 | $-1.26 | $-1.20 | $-0.81 | $-0.72 | $-0.85 | $-0.62 | $-0.56 | $-0.58 | $-0.45 |
| EBITDA | -$112.4M | -$125.0M | -$94.1M | -$83.8M | -$80.0M | -$57.1M | -$48.9M | -$49.8M | -$37.3M | -$31.1M | -$27.0M | -$21.8M |
| Operating cash flow | -$100.3M | -$106.5M | -$70.0M | -$61.9M | -$54.8M | -$54.4M | -$39.2M | -$36.9M | -$24.8M | -$33.8M | -$25.1M | -$23.0M |
| Free cash flow | -$100.4M | -$106.7M | -$70.1M | -$62.0M | -$55.0M | -$54.6M | -$39.8M | -$37.1M | -$24.9M | -$33.8M | -$25.2M | -$23.0M |
| Diluted shares | 71.8M | 71.5M | 65.6M | 63.8M | 63.8M | 63.7M | 60.7M | 54.9M | 54.7M | 51.0M | 44.5M | 44.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $48.9M | $114.4M | $354.7M | $57.8M | $49.1M | $55.1M |
| Short-term investments | $450.3M | $482.4M | $359.9M | $439.6M | $507.7M | $534.7M |
| Total debt | $75.2M | $75.0M | $74.8M | $74.6M | $74.5M | $50.9M |
| Total assets | $533.0M | $621.7M | $734.7M | $517.5M | $578.5M | $610.2M |
| Total liabilities | $125.2M | $122.0M | $130.2M | $118.6M | $110.3M | $75.2M |
| Shareholders' equity | $407.8M | $499.7M | $604.5M | $398.9M | $468.3M | $535.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology